Objective: The present study investigated the efficacy and tolerability of escitalopram in the prevention of relapse of major depressive disorder (MDD) in older patients who had responded to acute treatment with escitalopram. Method: A total of 405 patients who were aged 65 years or older with a primary diagnosis of MDD ( according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) and a Montgomery-Asberg Depression Rating Scale ( MADRS) total score of 22 or more received 12-week, open-label escitalopram 10 or 20 mg per day treatment. Remitters ( MADRS <= 12) were randomized to 24-week double-blind treatment with escitalopram or placebo. The primary efficacy parameter was the time to relapse, defined as eithe...
Gang Wang,1 Xiumin You,2 Xueyi Wang,3 Xiufeng Xu,4 Ludong Bai,5 Jian Xie,6 Zhijian Yao,7 QiZhong Yi,...
Background: The present prospective, open labelled study was designed to evaluate the efficacy and t...
BACKGROUND: Depressive illness in older people causes significant suffering and health service utili...
International audienceBACKGROUND: Escitalopram has shown efficacy and tolerability in the prevention...
Severe depression accounts for one-third of depressed patients. Increasing severity of depression us...
博士(医学) 乙第2900号(主論文の要旨、要約、審査結果の要旨、本文)著者名:大下隆司・河野美帆,タイトル:12~17歳の大うつ病性障害患者に対する第一選択薬としてのescitalopramの臨床的...
Abstract Background Escitalopram is licensed for use at doses up to 20 mg but is used clinically at ...
old-old patients with major depression more likely to relapse than young-old patients during continu...
Background: Although pharmacological and psychological interventions are both effective for major de...
BACKGROUND: Although pharmacological and psychological interventions are both effective for major de...
BACKGROUND: Randomized controlled clinical trials have demonstrated that escitalopram is efficacious...
Evidence of efficacy of new drugs is based on clinical studies which include highly selected patient...
Background: Findings of substantial remaining morbidity in treated major depressive disorder (MDD) l...
Objective: To establish the efficacy and tolerability of continuing treatment with antidepressants i...
Objective: To establish the efficacy and tolerability of continuing treatment with antidepressants i...
Gang Wang,1 Xiumin You,2 Xueyi Wang,3 Xiufeng Xu,4 Ludong Bai,5 Jian Xie,6 Zhijian Yao,7 QiZhong Yi,...
Background: The present prospective, open labelled study was designed to evaluate the efficacy and t...
BACKGROUND: Depressive illness in older people causes significant suffering and health service utili...
International audienceBACKGROUND: Escitalopram has shown efficacy and tolerability in the prevention...
Severe depression accounts for one-third of depressed patients. Increasing severity of depression us...
博士(医学) 乙第2900号(主論文の要旨、要約、審査結果の要旨、本文)著者名:大下隆司・河野美帆,タイトル:12~17歳の大うつ病性障害患者に対する第一選択薬としてのescitalopramの臨床的...
Abstract Background Escitalopram is licensed for use at doses up to 20 mg but is used clinically at ...
old-old patients with major depression more likely to relapse than young-old patients during continu...
Background: Although pharmacological and psychological interventions are both effective for major de...
BACKGROUND: Although pharmacological and psychological interventions are both effective for major de...
BACKGROUND: Randomized controlled clinical trials have demonstrated that escitalopram is efficacious...
Evidence of efficacy of new drugs is based on clinical studies which include highly selected patient...
Background: Findings of substantial remaining morbidity in treated major depressive disorder (MDD) l...
Objective: To establish the efficacy and tolerability of continuing treatment with antidepressants i...
Objective: To establish the efficacy and tolerability of continuing treatment with antidepressants i...
Gang Wang,1 Xiumin You,2 Xueyi Wang,3 Xiufeng Xu,4 Ludong Bai,5 Jian Xie,6 Zhijian Yao,7 QiZhong Yi,...
Background: The present prospective, open labelled study was designed to evaluate the efficacy and t...
BACKGROUND: Depressive illness in older people causes significant suffering and health service utili...